Summary:

HER2 amplification heterogeneity is associated with resistance to trastuzumab emtansine in the neoadjuvant setting, emphasizing the importance of assessing whether heterogeneous HER2-positive cancers require different treatment pathways.

See related article by Metzger Filho et al., p. 2474.

©2021 American Association for Cancer Research
2021
American Association for Cancer Research
You do not currently have access to this content.